References
- AmlotPLRawlingsEFernandoONProlonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantationTransplantation1995607487567570988
- KahanBDRajagopalanPRHallMReduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study GroupTransplantation19996727628410075594
- NashanBMooreRAmlotPSchmidtAGAbeywickramaKSoulillouJPRandomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study GroupLancet1997350119311989652559
- VincentiFde AndresABeckerTInterleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipientsTransplant Int200619446457
- MatasAJGillighamKJPayneWDNajarianJSThe impact of an acute rejection episodes on long-term renal allograft survival (t1/2)Transplantation1994578578598154032
- TesiRJHenryMLElkhammasEAFurgusonRMPredictors of long-term primary cadaveric renal transplant survivalClin Transplant19937345352
- FurgusonRAcute rejection episodes: best predictor of long-term primary cadaveric renal transplant survivalClin Transplant199483283318061375
- HibberdADTrevillianJHWlodarzcykJHCancer risk associated with ATG/OKT3 in renal transplantationTransplant Proc1999311271127210083567
- SwinnenLJCostanzo-NordinMRFisherSGIncreased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipientsN Eng J Med199032317231728
- WebsterACPlayfordEGHigginsGChapmanJRCraigJCInterleukin 2 receptor antagonists for renal transplant recipients: a metaanalysis of randomized trialsTransplantation20047716617614742976
- CockcroftDWGaultMHPrediction of creatinine clearance from serum creatinineNephron19761631411244564
- WabbijnMBalkAHvan DormburgRTTen-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptorExp Clin Transplant2004220120715859929
- BeaudreuilSDurrbachANouryJLong-term results (10 years) of a prospektice trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therpy in kidney transplantationTransplant Int200619814820
- KyllönenLEEklundBHPesonenEJSamelaKTSingle bolus antitymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine tripple immunosuppression: efficacy and safetyTransplantation200784758217627241
- ChapmanJRWebsterACCancer after renal transplantation: The next challengeAm J Transplant2004484184215147414
- KasiskeBLSnyderJJGilbertsonDTWangCCancer after kidney transplantation in the United StatesAm J Transplant2004490591315147424
- KesslerMJayNMolleRGuilleminFExcess risk of cancer in renal transplant patientsTransplant Int200619908914